Study to Evaluate the Safety and Efficacy of GS-5423 and GS-2872 in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection
Brief description of study
The primary objective of this study is to evaluate the safety and tolerability of a combination of the broadly neutralizing antibodies (bNAbs) GS-5423 and GS-2872 in combination with the HIV capsid inhibitor lenacapavir (LEN).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
HIV-1
-
Age: Between 18 Years - 65 Years
-
Gender: All
Male and Female, Age 18-65, On first-line antiretroviral therapy (ART) for ≥ 2 years
Updated on
09 Mar 2024.
Study ID: 849990
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting